New Mexico Tech Monitor
SEE OTHER BRANDS

Exploring the science and technology news of New Mexico

New Mexico Tech Monitor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.

Press releases published on May 14, 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential …

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of …

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by …

zSpace Reports First Quarter 2025 Financial Results

zSpace Reports First Quarter 2025 Financial Results

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in augmented and virtual reality solutions for education, is announcing its financial results for the three months ended March 31, 2025. “We are …

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax …

AGM Group Holdings Inc. Announces 50 for 1 Share Consolidation

AGM Group Holdings Inc. Announces 50 for 1 Share Consolidation

Beijing, May 14, 2025 (GLOBE NEWSWIRE) -- AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today …

Codexis Reports First Quarter 2025 Financial Results

Codexis Reports First Quarter 2025 Financial Results

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading …

David Boies joins Rumble legal team in case against Google

David Boies joins Rumble legal team in case against Google

LONGBOAT KEY, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Rumble (NASDAQ:RUM), the video-sharing platform and cloud services provider, today announced that prominent lawyer David Boies, of the firm Boies Schiller Flexner LLP, has joined the litigation team in …

Korro to Participate in Upcoming Investor Conferences

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram …

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

-  Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD -  Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3 …

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

Expanded life science and industrial portfolio with six additional life science products in development Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets Up to $4.5 million …

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s …

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of …

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in …

Snail, Inc. Reports First Quarter 2025 Financial Results

Snail, Inc. Reports First Quarter 2025 Financial Results

CULVER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) --  Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for its first …

dLocal Reports 2025 First Quarter Financial Results

dLocal Reports 2025 First Quarter Financial Results

Record highs across key financial and operational metrics. TPV milestone of US$8 billion, +53% YoY and +5% QoQ. In constant currency, TPV increased +72% YoY. Revenue and gross profit record highs of US$217 million and US$85 million. Continued geographic …

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial …

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service